

ASX release

18 October 2016

AtCor wins Frost & Sullivan's 2016 Diagnostic Devices Award

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor® system for advanced hypertension management, announced today that it has been awarded the Frost & Sullivan Asia Pacific 2016 Diagnostic Devices in Hypertension Management Customer Value Leadership Award.

The Frost & Sullivan Awards recognise best-in-class companies in regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development.

Frost & Sullivan partner Rhenu Buller said: "AtCor Medical had an outstanding performance in 2015 and we are pleased to award the team for their relentless efforts. We look forward to seeing even greater levels of performance in the future."

AtCor was recognised for its work in helping to diagnose pre-hypertension, and assisting in the determination of medication type and dose.

AtCor Medical CEO Duncan Ross said: "AtCor is honoured to receive this prestigious award. It recognises the breadth of our expertise and commitment to the industry. We will continue to invest in developing our products to help improve the health and lives of patients in Asia Pacific and around the globe."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements. SphygmoCor is essential for hypertension management.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact (AtCor):

Media enquiries to:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 8815 8811

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282
or a.rambukwella@fcr.com.au